Logo image of ICVX

ICOSAVAX INC (ICVX) Stock Fundamental Analysis

NASDAQ:ICVX - US45114M1099 - Common Stock

15.31 USD
-0.14 (-0.91%)
Last: 2/16/2024, 8:05:55 PM
15.39 USD
+0.08 (+0.52%)
After Hours: 2/16/2024, 8:05:55 PM
Fundamental Rating

3

ICVX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 547 industry peers in the Biotechnology industry. While ICVX has a great health rating, there are worries on its profitability. ICVX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ICVX had negative earnings in the past year.
ICVX had a negative operating cash flow in the past year.
ICVX Yearly Net Income VS EBIT VS OCF VS FCFICVX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

ICVX has a Return On Assets of -38.48%. This is in the better half of the industry: ICVX outperforms 62.67% of its industry peers.
ICVX has a Return On Equity of -41.61%. This is in the better half of the industry: ICVX outperforms 71.96% of its industry peers.
Industry RankSector Rank
ROA -38.48%
ROE -41.61%
ROIC N/A
ROA(3y)-59.36%
ROA(5y)N/A
ROE(3y)-206.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ICVX Yearly ROA, ROE, ROICICVX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 -100 -200 -300 -400 -500

1.3 Margins

ICVX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ICVX Yearly Profit, Operating, Gross MarginsICVX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 -5K -10K -15K

More info and screens

8

2. Health

2.1 Basic Checks

ICVX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ICVX has been increased compared to 1 year ago.
ICVX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ICVX Yearly Shares OutstandingICVX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 10M 20M 30M 40M
ICVX Yearly Total Debt VS Total AssetsICVX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 22.57 indicates that ICVX is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 22.57, ICVX belongs to the best of the industry, outperforming 92.74% of the companies in the same industry.
There is no outstanding debt for ICVX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.57
ROIC/WACCN/A
WACC10.99%
ICVX Yearly LT Debt VS Equity VS FCFICVX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 0 100M 200M

2.3 Liquidity

A Current Ratio of 18.10 indicates that ICVX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 18.10, ICVX belongs to the best of the industry, outperforming 91.55% of the companies in the same industry.
ICVX has a Quick Ratio of 18.10. This indicates that ICVX is financially healthy and has no problem in meeting its short term obligations.
ICVX's Quick ratio of 18.10 is amongst the best of the industry. ICVX outperforms 91.55% of its industry peers.
Industry RankSector Rank
Current Ratio 18.1
Quick Ratio 18.1
ICVX Yearly Current Assets VS Current LiabilitesICVX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

ICVX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.83%.
The Revenue for ICVX has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-1.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ICVX will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.96% on average per year.
ICVX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 194.45% yearly.
EPS Next Y5.52%
EPS Next 2Y3.44%
EPS Next 3Y-1.53%
EPS Next 5Y18.96%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.57%
Revenue Next 5Y194.45%

3.3 Evolution

ICVX Yearly Revenue VS EstimatesICVX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2025 2026 2027 2028 2029 2030 200M 400M 600M
ICVX Yearly EPS VS EstimatesICVX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ICVX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ICVX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ICVX Price Earnings VS Forward Price EarningsICVX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ICVX Per share dataICVX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.44%
EPS Next 3Y-1.53%

More info and screens

0

5. Dividend

5.1 Amount

ICVX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ICOSAVAX INC

NASDAQ:ICVX (2/16/2024, 8:05:55 PM)

After market: 15.39 +0.08 (+0.52%)

15.31

-0.14 (-0.91%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2023-11-14/amc
Earnings (Next)N/A N/A
Inst Owners1.88%
Inst Owner Change-0.02%
Ins Owners14.46%
Ins Owner Change0%
Market Cap766.88M
Analysts78.33
Price Target18.87 (23.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.86%
Min EPS beat(2)3.68%
Max EPS beat(2)24.05%
EPS beat(4)4
Avg EPS beat(4)7.7%
Min EPS beat(4)1.1%
Max EPS beat(4)24.05%
EPS beat(8)5
Avg EPS beat(8)1.17%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)1
Avg Revenue beat(8)-70.27%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-20.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.77%
EPS NY rev (1m)0%
EPS NY rev (3m)9.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.3
P/tB 3.3
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-1.47
FCFYN/A
OCF(TTM)-1.37
OCFYN/A
SpS0
BVpS4.64
TBVpS4.64
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.48%
ROE -41.61%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-59.36%
ROA(5y)N/A
ROE(3y)-206.85%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 179.55%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 18.1
Quick Ratio 18.1
Altman-Z 22.57
F-Score3
WACC10.99%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)643.03%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y5.52%
EPS Next 2Y3.44%
EPS Next 3Y-1.53%
EPS Next 5Y18.96%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y3.57%
Revenue Next 5Y194.45%
EBIT growth 1Y-20.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-84.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.04%
OCF growth 3YN/A
OCF growth 5YN/A